Intravesical administration of the Bisphosphocin® Nu-8 to rodents infected with E. coli demonstrated up to 97% inhibition of E. coli growth compared to no effect in a vehicle control group. SARASOTA, Fla., Oct. 7, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT,...
Combination of ruvonoflast and semaglutide produced greater reductions in hsCRP versus semaglutide monotherapy
Full one-year results from the KYSA-8 registrational trial in stiff person syndrome to be reported, demonstrating sustained clinical benefit and a well-tolerated safety profile with no high-grade CRS or ICANS and no cases of IEC-HS
Next steps at Cottaweg: Baumi, Brajan and Rocco have all made further progress in their recoveries. While Baumi took part in brief spells of team training on Tuesday for the first time since his injur...
Seattle’s coach shares what he knows about the injury the Pro Bowl defensive lineman got late in Seattle’s win over the Chargers.
